Home Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
 

Keywords :   


Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx

2013-12-03 00:36:37| Biotech - Topix.net

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Tags: of million rx pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »